Safety and Biomarker Analysis of NRG-LU004: Phase I Trial of Accelerated or Conventionally Fractionated Radiation Therapy Combined With Durvalumab in Programmed Death Ligand-1–High Locally Advanced Non-small Cell Lung Cancer
Year: 2026
Type: article
Study design: Clinical Trial
Authors: Steven H. Lin, Stephanie L. Pugh, Diane Marie Del Valle, Vladimir Roudko, Martin J. Edelman, Anthony J. Doemer, Charles B. Simone, Kai Nie, Tia Rizakos, Alisha Mugunthan, Ruihua Zhang, Geoffrey Kelly, Noam Beckmann, Ryan C. Thompson, Seunghee Kim-Schulze, Edgar Gonzalez-Kozlova, Saumil Gandhi, Sai Bikkina, Nagla Karim, Xinglei Shen, Shahed N. Badiyan, Kristin A. Higgins, Arnab Chakravarti, Maria Werner-Wasik, John M. Schallenkamp, Mayte Suarez-Farinas, Sacha Gnjatic, Anne S. Tsao, Jeffrey D. Bradley
Institutions: The University of Texas MD Anderson Cancer Center, NRG Oncology, Icahn School of Medicine at Mount Sinai, Fox Chase Cancer Center, Henry Ford Health, Henry Ford Hospital, Memorial Sloan Kettering Cancer Center, Augusta University, University of Kansas Medical Center, The University of Texas Southwestern Medical Center, City of Hope, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Thomas Jefferson University Hospital, Billings Clinic, University of Pennsylvania
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: National Cancer Institute
OpenAlex ID: W7212374756